hA19-SN-38 antibody-drug conjugate - Immunomedics

Drug Profile

hA19-SN-38 antibody-drug conjugate - Immunomedics

Alternative Names: Anti-CD19 antibody-SN-38 antibody-drug conjugate - Immunomedics; hA19-SN-38 ADC - Immunomedics

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Immunomedics
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action CD19 antigen modulators; DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 15 Nov 2016 Immunomedics has patent protection for hA19-SN-38 antibody drug conjugate in USA
  • 15 Nov 2016 Early research in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top